HN30 Stock Chart & Stats
€0.04
€0.00(0.00%)
At close: 4:00 PM EDT
€0.04
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€0.03 - €0.08
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€2.91M
Enterprise Value€4.75
Total Cash (Recent Filing)€762.36K
Total Debt (Recent Filing)€348.35K
Price to Earnings (P/E)―
Beta1.83
Next Earnings
Dec 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding62,506,542
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)3.29
Price to Sales (P/S)0.00
P/FCF Ratio-5.91
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Improved 2025 Balance SheetThe return to positive equity alongside modest leverage provides a stronger financial base than in 2023–2024. This may improve resilience and preserve funding flexibility over the next several months, although the historical volatility remains important.
Rebuilding Asset BaseA larger asset base can support future development and operating activity if management converts those resources into commercial progress. The rebuilding represents tangible balance-sheet improvement compared with prior periods, supporting greater organizational capacity.
Reduced Cash OutflowA reduction in cash outflows lowers the immediate pace of capital consumption compared with the trough years. While the company remains cash-flow negative, this improvement could extend funding runway and create more time to develop operations or secure additional capital.
Bears Say
No Recurring RevenueThe absence of recurring revenue leaves the business without demonstrated commercial traction or internally generated operating support. This makes future progress dependent on successfully establishing monetizable products or activities, increasing execution risk over the next several quarters.
Persistent Operating LossesContinued negative operating earnings show that the core business has not yet reached profitability or demonstrated improving earnings power. Without a stable revenue stream, persistent losses can erode financial resources and constrain investment in future growth initiatives.
Ongoing Cash BurnNegative operating and free cash flow across every reported year indicates that operations do not currently fund themselves. Continued dependence on external capital can limit strategic flexibility and expose the company to funding pressure while commercial development remains unproven.
Restart Life Sciences News
HN30 FAQ
What was Restart Life Sciences’s price range in the past 12 months?
Restart Life Sciences lowest stock price was €0.03 and its highest was €0.08 in the past 12 months.
What is Restart Life Sciences’s market cap?
Restart Life Sciences’s market cap is €2.91M.
When is Restart Life Sciences’s upcoming earnings report date?
Restart Life Sciences’s upcoming earnings report date is Dec 02, 2026 which is in 64 days.
How were Restart Life Sciences’s earnings last quarter?
Restart Life Sciences released its earnings results on Aug 27, 2026. The company reported -€0.011 earnings per share for the quarter.
Is Restart Life Sciences overvalued?
According to Wall Street analysts Restart Life Sciences’s price is currently Overvalued.
Does Restart Life Sciences pay dividends?
Restart Life Sciences does not currently pay dividends.
What is Restart Life Sciences’s EPS estimate?
Restart Life Sciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Restart Life Sciences have?
Restart Life Sciences has 62,506,542 shares outstanding.
What happened to Restart Life Sciences’s price movement after its last earnings report?
Restart Life Sciences reported an EPS of -€0.011 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Restart Life Sciences?
Currently, no hedge funds are holding shares in DE:HN30
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Restart Life Sciences
Operating internationally through its various subsidiaries, Restart Life Sciences Corp. functions as a biotechnology firm. Its core endeavors include the creation of natural therapeutic remedies tailored for individuals with autism spectrum disorder, the development of health-promoting foods designed for comprehensive mind and body wellness, and the execution of a psilocybin clinical trial aimed at fragile X syndrome. Founded in 2004 and based in Vancouver, Canada, the company adopted its current name in November 2024, having previously been known as Nova Mentis Life Science Corp.